Skip to main content
HLB SCIENCE Inc. logo

HLB SCIENCE Inc. — Investor Relations & Filings

Ticker · 343090 ISIN · KR7343090007 KO Professional, scientific and technical activities
Open in API
Filings indexed 187 across all filing types
Latest filing 2022-03-07 AGM Information
Country KR South Korea
Listing KO 343090

About HLB SCIENCE Inc.

https://hlbscience.com/eng/index.php

HLB SCIENCE Inc. is a biopharmaceutical company specializing in the development of innovative drugs and diagnostics for infectious and immune-related diseases. The company's primary research focuses on creating therapeutics for sepsis, superbacteria infections, and Alzheimer's disease. Its key pipeline candidate for sepsis, DD-S052P, is a novel antibiotic designed to eliminate both bacteria and their associated endotoxins to mitigate cytokine storms. For Alzheimer's disease, HLB SCIENCE is advancing DD-A279, a treatment that modulates lipopolysaccharides (LPS) and gram-negative bacteria in the central nervous system. This therapeutic effort is complemented by the development of DD-A514, a diagnostic kit for the early detection of Alzheimer's.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Dandi Bioscience. It contains the meeting agenda, details on voting procedures, and management information, which are standard components of a Proxy Solicitation statement. In the context of Korean corporate filings, this document serves as the official material sent to shareholders to inform them of the meeting and request their votes, fitting the definition of a Proxy Solicitation & Information Statement.
2022-03-07 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) issued by Dandi Bioscience. It outlines the agenda for the upcoming Annual General Meeting, including financial statement approval, director appointments, and a stock split proposal. Since this document provides the information necessary for shareholders to vote and attend the meeting, it falls under the category of Proxy Solicitation & Information Statement.
2022-02-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in South Korea. This type of filing is used to disclose insider transactions, such as stock acquisitions or changes in holdings by company directors or major shareholders. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2022-02-16 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the exercise of stock options (주식매수선택권 행사) by employees and executives of Dandi Bio. It details the number of shares issued, the impact on total outstanding shares, and the remaining stock option balance. This type of disclosure regarding capital changes and share issuance falls under the 'Share Issue/Capital Change' category.
2022-02-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard disclosure for insider share transactions or changes in ownership status by company directors and executives, which corresponds to the 'Director's Dealing' category.
2022-01-11 Korean
주식매수선택권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Dandi Bio regarding the exercise of stock options (주식매수선택권 행사). It details the number of shares exercised, the impact on total outstanding shares, the listing date for new shares, and the remaining stock options. This type of disclosure regarding changes in capital structure due to stock option exercises falls under the category of share issues or capital changes.
2022-01-06 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.